CVR Medical

CVR Energy reported Q1 2026 EPS of -1.24 USD, well below the expected -0.38 USD, while revenue of 1.98 billion USD exceeded estimates. The company recorded a consolidated net loss of 160 million USD and adjusted EBITDA of 37 million USD. Results were hurt by unrealized losses on derivative transactions and high RIN prices; the stock fell 1.58% in premarket trading. For Q2 2026 CVR expects throughput of 200,000–215,000 bpd and direct operating costs of 110–120 million USD; strategic adjustments to the crude slate are intended to improve margins. » More on de.investing.com

CVR Energy’s stock rose to $33.25, marking a 52-week high and bringing market capitalization to about $3.33 billion. The yield is 11.49% and the company has paid dividends for 12 consecutive years. Despite a strong price gain of 39.4% over the past year (58.45% in six months), CVR reported an adjusted loss per share of $0.23 in Q2/2025 (expectation: -$0.06), but beat revenue expectations with $1.76 billion. Analyst notes indicate the stock may be trading above its fair value; gross profit margin remained weak at 1.63%. » More on de.investing.com

CVR Energy’s stock rose to a 52-week high of 32.67 USD and has gained 70.7% over the past six months; year-to-date the increase is 49.4%. InvestingPro cites a dividend yield of 11.35% and notes 12 consecutive years of dividend payments, but considers the stock to be above its fair value. For Q2 2025 the company reported an adjusted loss per share of 0.23 USD (expectation: -0.06 USD) on revenue of 1.76 billion USD (expectation: 1.68 billion USD), after which the stock fell sharply in after-hours trading. » More on de.investing.com